Jack Allen
Stock Analyst at Baird
(0)
# 4546
Out of 5,218 analysts
48
Total ratings
35.29%
Success rate
-14.07%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CARISMA Therapeutics | Downgrades: Neutral | 10 1 | 0.4 | 150% | 3 | Dec 12, 2024 | |
MiNK Therapeutics | Maintains: Outperform | 8 4 | 0.64 | 525% | 2 | Nov 15, 2024 | |
Vor Biopharma | Maintains: Outperform | 22 14 | 0.98 | 1328.57% | 3 | Nov 8, 2024 | |
Arcellx | Maintains: Outperform | 77 106 | 83.86 | 26.4% | 5 | Nov 6, 2024 | |
Intellia Therapeutic... | Maintains: Neutral | 24 18 | 12.89 | 39.64% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 180 180 | 21.94 | 720.42% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 140 120 | 6.36 | 1786.79% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 8 | 3.71 | 115.63% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 46 52 | 43.75 | 18.86% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 84 | 28.93 | 190.36% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 200 25 | n/a | n/a | 3 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 8 | 2.06 | 288.35% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 21 6 | n/a | n/a | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 12 | 1.89 | 534.92% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 5 | 0.5 | 900% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 9 | n/a | n/a | 1 | Sep 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 28 | 1.82 | 1438.46% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 6 9 | 6.25 | 44% | 1 | Oct 7, 2021 |